title: The role of α-zearalanol in reversing bone loss induced by ovarian hormone deficiency in rats.
abstract: To assess the ability of α-zearalanol (α-ZAL) to prevent bone loss in an ovariectomized (OVX) rat model of osteoporosis, α-ZAL was administered intragastrically to rats. After 35 days, the total body bone mineral density (BMD) was assessed in all rats. All sections were processed for immunohistochemistry and hematoxylin and eosin staining. One-way ANOVA and an LSD multiple-range test were used to determine the significant differences between groups. BMD was lower in the OVX and OVX + α-ZAL high-dose (OVX + High) groups compared to the sham-operated (Sham), OVX + 17β-ethinylestradiol (OVX + E(2)), OVX + α-ZAL medium-dose (OVX + Medium) and OVX + α-ZAL low-dose (OVX + Low) groups (P < 0.05). Clear bone trabeculae arrangements were observed in the OVX + E(2,) OVX + Medium and OVX + Low groups. The expressions of bone morphogenetic proteins and basic fibroblast growth factor were up-regulated in the OVX + E(2), OVX + Medium and OVX + Low groups compared to the OVX and OVX + High groups (P < 0.05). The OVX + E(2), OVX + Medium and OVX + Low groups showed lower levels of bone Gla protein, bone alkaline phosphatase, tartrate-resistant acid phosphatase and tumor necrosis factor α expressions than the OVX and OVX + High groups (P < 0.05). The administration of α-ZAL to ovariectomized rats reverses bone loss and prevents osteoporosis.
authors.affiliation: Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
authors.forename: Shaohui
authors.initials: S
authors.lastname: Zong
authors.forename: Bo
authors.initials: B
authors.lastname: Wei
authors.forename: Chunxiang
authors.initials: C
authors.lastname: Xiong
authors.forename: Yuxi
authors.initials: Y
authors.lastname: Zhao
authors.forename: Gaofeng
authors.initials: G
authors.lastname: Zeng
mesh_terms: D000135:Acid Phosphatase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D019485:Bone Morphogenetic Proteins / Q000378:metabolism; D001862:Bone Resorption / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004967:Estrogens / Q000172:deficiency*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D007527:Isoenzymes / Q000378:metabolism; D015675:Osteocalcin / Q000378:metabolism; D010052:Ovariectomy; D010053:Ovary / Q000187:drug effects / Q000378:metabolism* / Q000601:surgery; D011374:Progesterone / Q000172:deficiency*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling; D000071681:Tartrate-Resistant Acid Phosphatase; D013977:Tibia / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015029:Zeranol / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D019485:Bone Morphogenetic Proteins; D004967:Estrogens; D007527:Isoenzymes; D014409:Tumor Necrosis Factor-alpha; D016222:Fibroblast Growth Factor 2; D015675:Osteocalcin; D011374:Progesterone; D015029:Zeranol; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase